Lawrence KM, et al. - A retrospective cohort study was carried out to assess the impact of continuous treprostinil in infants with severe pulmonary hypertension associated with congenital diaphragmatic hernia (CDH) on specific markers of pulmonary hypertension severity and to report the safety and tolerability of treprostinil. From January 2011 to September 2016, a retrospective cohort study of infants with CDH-associated pulmonary hypertension treated with treprostinil was conducted. They used Fisher exact tests, Wilcoxon-rank sum tests, and mixed-effects models for this investigation. The present data indicated that treprostinil use was correlated with improved severity of pulmonary hypertension assessed by echocardiogram and decreased B-type natriuretic peptide (BNP), with no significant side effects.